

Opportunity:

Chemotherapy Induced Peripheral Neuropathy (CIPN)

CIPN Overview

13 Million

Annual cases of CIPN total 3 Million in the US and 13 Million globally.

High % of Patients

Up to 90% of patients may suffer from CIPN. Nearly 50% of cases symptoms can persist 6 years after receiving chemotherapy treatment.

+ 10B

The annual global CIPN market size is estimated to be worth USD 10 billion.

Significant Unmet Need

No treatments are available that prevent CIPN and therapies have only been shown to be moderately effective in alleviating symptoms.

BXQ-350 Highlights

- ➔ Preclinical and clinical evidence suggests that **BXQ-350 prevents/reverses CIPN**
- ➔ Ongoing Phase 1 PK/PD proof-of-concept trial
 - Internal data readout 4Q23